The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.
Search Terms:
Investigator: Anne Fagan
Project Title: Evaluation of CSF aSynuclein as a novel prognostic biomarker
Date: December 21, 2021 at 5:02 pm
Request ID: T1817-A
Aim 1: 1) To elucidate the relationship between CSF aSN levels, clinical/cognitive measures and other AD-related CSF biomarkers.
Aim 2: 2) To evaluate the utility of CSF aSN as a prognostic biomarker that is predictive of time until death.
Aim 3:
Aim 4:
Investigator: Gregory S Day
Project Title: RT-QuIC testing in “preclinical” CJD
Date: December 21, 2021 at 5:02 pm
Request ID: T1904
Aim 1: To determine the sensitivity of RT-QuIC testing in CSF obtained from research participants who were eventually diagnosed with sporadic CJD.
Aim 2:
Aim 3:
Aim 4:
Investigator: Randall Bateman
Project Title: ApoE proteoforms in the human CNS and validation of translational ApoE pharmacodynamic markers
Date: December 21, 2021 at 5:02 pm
Request ID: T1903
Aim 1: Aim 1: Characterize ApoE truncations, fragments, and post-translational modifications found in human brain, CSF and plasma.
Aim 2: Aim 2: Target ApoE and A� kinetics in an AD animal model expressing human ApoE and human A� treated with an ApoE LDLR upregulation (clearance activator) or ASO ApoE knockdown (production inhibitor) to assess whether targeting ApoE levels changes ApoE and A� kinetics.
Aim 3:
Aim 4:
Investigator: Joseph M Castellano
Project Title: Plasma protein-mediated effects of ApoE4 expression on brain in AD
Date: December 21, 2021 at 5:02 pm
Request ID: T1902
Aim 1: To investigate plasma protein differences between cognitively normal human subjects homozygous for APOE-e4 or APOE-e3 alleles using aptamer-based protein platform for ~1000 proteins to identify pathways and regulators of peripheral dysfunction impacting brain health.
Aim 2:
Aim 3:
Aim 4:
Investigator: Dianne Langford
Project Title: Biomarkers to detect risk for disease, predict outcome and prevent impaired clearance of waste from the brain
Date: December 21, 2021 at 5:02 pm
Request ID: T2102
Aim 1: Determine if the (GT(n) repeat polymorphism of the NEFL gene is associated with with progressive cognitive impairment in AD
Aim 2: Determine if levels of NFL in blood associate with NEFL GT(n) repeats.
Aim 3: Determine of SNPS in the aquaporin 4 gene associate with greater brain levels of Tau and Abeta in blood and brain
Aim 4:
Investigator: Sharlee Climer
Project Title: Robust Alzheimer Disease Plasma-Based Diagnostic Tool that Cuts Across Ancestral Lines and COVID-19 Impacts
Date: December 21, 2021 at 5:02 pm
Request ID: T2101
Aim 1: Generate genomics, proteomics, metabolomics, and lipidomics data for AD cases and controls, including African American volunteers, from plasma samples drawn prior to and following the COVID-19 pandemic.
Aim 2: Use a multi-pronged approach to identify high-dimensional biomarker signatures that can identify AD-associated interaction networks within and among the -omics data and create a plasma-based diagnostic tool.
Aim 3:
Aim 4:
Investigator: Jaime Grutzendler
Project Title: Cell biology of PLD3 regulation in Alzheimer disease
Date: December 21, 2021 at 5:02 pm
Request ID: T2023
Aim 1: Superresolution imaging of PLD3 associated lysosomal partners in AD postmortem brain
Aim 2: Characterization of PLD3 effects on AD neuropathology
Aim 3:
Aim 4:
Investigator: Richard I. Morimoto
Project Title: Drug Discovery to Ameliorate Proteostasis Failure in Tauopathies
Date: December 21, 2021 at 5:02 pm
Request ID: T2002
Aim 1: To develop and validate a panel of proteostasis sensors and reporters for all arms of the Proteostasis Network (PN) that robustly and quantitatively reports on each branch of the PN in the context of mutant Tau and the effects of aging.
Aim 2: To test the hypothesis that the age-dependent deficiencies in PN capacity in animal and cell models of Tauopathy can be reset by pharmacologic regulation of the PN employing using small molecule proteostasis regulators (PRs).
Aim 3:
Aim 4:
Investigator: Eran Hornstein
Project Title: miRNAs as diagnostic biomarkers for Alzheimer’s disease
Date: December 21, 2021 at 5:02 pm
Request ID: T2001
Aim 1: Testing a microRNA classifier for FTD on an AD plasma cohort
Aim 2: Establishing plasma microRNAs as markers for differential diagnosis between AD and FTD
Aim 3: Developing a machine learning algorithm for AD classification based on plasma microRNAs
Aim 4:
Investigator: Mar�a Isabel Behrens
Project Title: Role of senescence on the inverse association between Alzheimer’s Disease and and Cancer
Date: December 21, 2021 at 5:02 pm
Request ID: T1011-A
Aim 1: Quantify the number of senescent cells in frontal cortical brain tissue of CDR 0.5 (very early AD) and CDR 2-3 (moderate-advanced AD) patients, with and without a history of any type of cancer in the past
Aim 2: Quantify the number of senescent cells in frontal cortical brain tissue of CDR 0 patients, with and without a history of any type of cancer in the past
Aim 3:
Aim 4: